DEEP TECH PLATFORM COMPANY · AMTZ, VISAKHAPATNAM
“We build platforms, not products.” By converging marine biotechnology, catechol chemistry, and advanced nanomaterials into scalable clinical engines, Akrivis turns complex biological insights into market-ready therapeutics — manufactured at giga-scale at AMTZ.
“We build platforms, not products. Each product is the expression of a platform; each platform is a body of knowledge that compounds.”
THE TRUST STACK
By anchoring operations inside Asia’s premier MedTech ecosystem and maintaining active regulatory clearances across CDSCO, US FDA, and European standards, Akrivis eliminates buyer skepticism at the point of first contact.
CDSCO Licensed // US FDA Registered Facility Status // ISO Certified. Active seat on BIS MHD-20 — drafting national standards for advanced medical devices, aligning Indian innovation with EN ISO 13485 and European MDR.
8 Filed Patents // 23+ Validated Commercial Products across therapeutic, device, and cosmeceutical portfolios.
THE FOUNDER MATRIX
By uniting a veteran Surgeon-Scientist who understands real-world surgical trauma with a Cancer Biologist who commands ultra-rigorous cellular mechanics, Akrivis achieves a convergence that transforms biological complexity into scalable, first-in-class bio-solutions.
Surgeon-Scientist: Engineering out the limitations of invasive surgery
Dr. Sarat Babu Janipalli brings 20+ years of clinical architecture and surgical reality. By identifying unmet surgical needs at the point of care, he drives the development of non-invasive alternatives — the force behind TympanoSeal™.
20+ years clinical surgery · Founder & CEO · Platform architect · IP strategist
Cancer Biologist & Molecular Scientist: Commanding cellular precision
Dr. Vamshi Krishna Irlapati commands the ultra-rigorous cellular mechanics of oncology. Because he masters molecular pathways at the deepest level, Akrivis’s regenerative tissue platforms possess unmatched biological precision — the science behind SynExo™.
PhD Biotechnology · Co-Founder & CSO · Pre-clinical validation · Molecular logic
Clinical need meets cellular solution at manufacturing scale
By converging macro-application insight with micro-mechanism mastery, Akrivis accelerates from laboratory discovery to cGMP manufacturing — thereby ensuring every platform delivers both clinical efficacy and commercial scalability.
5+ active platforms · 8 filed patents · 23+ commercial products · cGMP at AMTZ
By converging marine biotechnology, catechol chemistry, and advanced nanomaterials into a unified platform architecture, Akrivis accelerates each discovery from laboratory insight to validated commercial product — thereby ensuring every platform compounds into the next.
Non-Invasive Tympanic Membrane Repair
A novel medical device for non-invasive tympanic membrane repair. Designed as a fifteen-minute in-clinic procedure, offering a non-surgical alternative to conventional tympanoplasty. Chronic suppurative otitis media affects approximately 65–330 million people globally (WHO, 2004), with a disproportionate burden in South and Southeast Asia.
Regenerative Therapeutics Platform
The core therapeutic platform spanning wound care, burn care, and regenerative medicine. Manufactured under cGMP at the AMTZ facility in Visakhapatnam.
Advanced Cosmeceutical Portfolio
Therapeutic and cosmetic formulations for aesthetic medicine, wound repair, and adjacent regenerative indications. European market access strategy supports international expansion.
In Partnership with Hemarina SA, France
Commercialisation of oxygenation technology developed by Hemarina SA of France. Topical applications in wound healing and aesthetic medicine.
Nanomaterials, Diagnostics & Emerging Technologies
A portfolio of emerging platforms spanning nanomaterials, collagen technologies, non-invasive diagnostics, and next-generation therapeutic delivery systems.
By separating high-stakes clinical innovation from scaled commercial delivery, Akrivis ensures each track receives the precise regulatory, manufacturing, and distribution architecture it demands.
Audience: Global Cosmetic, Wellness, & B2B Distributors. Active international consumer footprints including Harrods UK, SkinSeqnc Canada, and Southeast Asian markets.
Aesthetic Medicine
Approved
Dermal Care
Holista Colltech Partnership
Topical Oxygenation
Hemarina SA Partnership
Trichology
Approved
Cosmeceutical
Approved
By leveraging exclusive cross-border biotechnology alliances with global innovators like Holista Colltech Ltd, Akrivis delivers verified quantitative advantages that transform static data into enterprise lead-generation engines.
Verified 84x Bio-Availability Multiplier
Holista Colltech Alliance: By leveraging exclusive cross-border biotechnology alliances with global innovators like Holista Colltech Ltd (ASX: HCT), Akrivis delivers a verified 84x bio-availability multiplier over standard molecular weights.
Exclusive supply agreement with ASX-listed Holista Colltech Ltd (ASX: HCT) — delivering a verified 84x bio-availability multiplier over standard molecular weights.
SynExo™ Production Calculator
Giga-scale production: Illustrative estimates based on Akrivis manufacturing facility at AMTZ, Visakhapatnam. Actual yields vary based on production parameters.
A multidisciplinary leadership team architecting the convergence of clinical surgery, molecular biology, regulatory strategy, and global commercial scale.
Founder & CEO
A veteran Surgeon-Scientist who understands application, real-world surgical trauma, and patient needs. By engineering out the limitations of traditional invasive operations, Dr. Sarat drives the development of first-in-class non-invasive alternatives — the clinical force behind TympanoSeal™. Leads platform architecture, IP strategy, and regulatory navigation.
Co-Founder & Chief Scientific Officer
A powerhouse Cancer Biologist & Molecular Scientist who commands cellular pathways, tissue engineering, and molecular logic. Because he masters the ultra-rigorous cellular mechanics of oncology, Akrivis’s regenerative tissue platforms like SynExo™ possess unmatched biological precision.
Co-Founder & Chief Business Officer
Drives commercial strategy, international partnerships, and investor relations. Architect of the B2B distribution network spanning India, Europe, and the Middle East.
Founder — Private Equity & Strategic Finance
Prominent Chartered Accountant, educator, and community leader with over two decades of expertise in private equity, banking, and agripreneurship. Director of Agribid, an AI-driven platform empowering farmers.
Founder — International Operations
Manages international operations, entity coordination, and cross-border supply chain logistics. Anchors European distribution and partnership infrastructure.
Director — Partnerships & Business Development
A visionary business leader specializing in strategic scaling, high-value partnership acquisition, and robust revenue generation across both domestic Indian and global markets.
Director — Business Development
Spearheads strategic scaling, high-value partnership acquisition, and revenue acceleration across the Indian domestic market and key overseas territories.
Regulatory compliance and quality management systems underpinning every product in the portfolio.
Central Drugs Standard Control Organisation
Manufacturing licence for cosmeceutical and therapeutic formulations. Full commercial portfolio approved.
Cosmetics GMP
Good Manufacturing Practice for cosmetic products. Covers the AMTZ facility production lines for the entire cosmeceutical portfolio.
Quality Management Systems
Organisation-wide quality management system certification covering design, development, manufacturing, and distribution.
United States Food & Drug Administration
Facility registration and product listing for export-grade cosmeceutical formulations. Enables direct export through registered distribution channels.
Bureau of Indian Standards — Medical & Healthcare Devices
Institutional membership on the BIS MHD-20 committee — drafting national standards for medical and healthcare devices.
Independent Elemental Validation
Independent third-party validation of platform materials. Confirms elemental composition and purity across the commercial portfolio.
The Andhra Pradesh MedTech Zone (AMTZ) is Asia’s first integrated medical device manufacturing ecosystem. Akrivis operates its cGMP facility within AMTZ, providing access to shared infrastructure, regulatory support, and a cluster of complementary medical device manufacturers.
A curated network of technology providers, distribution partners, and institutional supporters enabling global reach from our AMTZ manufacturing base.
Morlaix, France
French marine biotechnology company specialising in oxygen-carrying molecules derived from Arenicola marina. Hemarina’s M101 molecule forms the basis of the HEMOSOME OxyRescue platform.
Exclusive India commercialisation rights
Kuala Lumpur, Malaysia (ASX: HCT)
ASX-listed biotechnology company specialising in nano-scale collagen extraction from ovine sources. Holista’s proprietary process achieves 84× greater dermal absorption than standard collagen.
Exclusive supply agreement
United Kingdom
Premium distribution channel for the EXOGLAM cosmeceutical range through Harrods and affiliated luxury retail networks.
Distribution PartnerCanada
Canadian distribution partner for the SynExo™ and EXOGLAM cosmeceutical portfolios.
Distribution PartnerMalaysia
Strategic partner for nano-collagen and cosmeceutical distribution across the Southeast Asian market.
PartnerIndia
Subsidiary focused on domestic Indian market distribution and brand development.
SubsidiaryAsia’s first integrated medical device manufacturing ecosystem. Akrivis operates its cGMP facility within AMTZ.
Nadupuru, Anakapalli District, Visakhapatnam, Andhra Pradesh 531019
Innovation hub providing incubation support, mentorship, and access to the broader Tata ecosystem for deep-tech startups.
IIT Hyderabad Campus, Kandi, Sangareddy, Telangana 502285
By routing each inbound inquiry through a purpose-built segmentation layer, Akrivis ensures every stakeholder receives precisely the information, access, and response architecture they require.
Access the Akrivis data room — financial projections, IP portfolio summary, cap table structure, and validated commercial traction metrics.
Request Data Room Access →Explore exclusive regional distribution rights across our 23+ product commercial portfolio.
Inquire About Regional Rights →Request peer-reviewed clinical data, technical whitepapers, and collaboration proposals for TympanoSeal™, SynExo™, or adjacent therapeutic platforms.
Request Clinical Documentation →Route your inquiry directly to the Akrivis leadership team. Each submission is triaged by intent and responded to within 2 business days.